person · Reporting owner
French Glendon E. III
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| EDAP TMS SAEDAP · Entity 6325 | Director | January 01, 2026 | January 10, 2026 |
| Pulmonx CorpLUNG · Entity 2359 | Director · President and CEO | September 01, 2026 | September 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
EDAP TMS SA
Report date January 01, 2026 · Filed January 10, 2026
This filing explicitly reported no securities owned.
Pulmonx Corp
Report date September 01, 2026 · Filed September 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,175,720 |
Reported balance
After 2026-09-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-01 · Sale · Disposed 4,098 · Balance 1,175,720 F1: These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units (the "RSUs") granted on March 1, 2023. F2: Includes 1,656 shares acquired by the reporting person under the Issuer's 2020 Employee Stock Purchase Plan on August 14, 2026. |
| Common StockSEC Table I · non-derivative | Direct | 1,137,936 |
Reported balance
After 2026-09-01 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-09-01 · Sale · Disposed 37,784 · Balance 1,137,936 F3: These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs granted on December 1, 2025. |
| Common StockSEC Table I · non-derivative | IndirectBy trust | 918,198 |
Reported balance
Holding disclosure · report date 2026-09-01 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 918,198 F4: The shares are held by the Glendon E French & Gayle French Trustees French Family Rev Trust UA DTD 08/29/2012, of which the reporting person and his spouse are trustees and beneficiaries. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units (the "RSUs") granted on March 1, 2023.
F2: Includes 1,656 shares acquired by the reporting person under the Issuer's 2020 Employee Stock Purchase Plan on August 14, 2026.
F3: These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs granted on December 1, 2025.
F4: The shares are held by the Glendon E French & Gayle French Trustees French Family Rev Trust UA DTD 08/29/2012, of which the reporting person and his spouse are trustees and beneficiaries.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 20, 2021 Filed Dec 4, 2021 00:08 UTC Amendment | Pulmonx Corp LUNG · Entity 2359 | Exercise / conversionCommon Stock | 10,000 | $2.20 | $22,000.00 |
DisclosureSEC source: 0001209191-21-067997 · doc4a.xml · nonDerivative · entry 1 French Glendon E. III · CIK 0001805624 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,259,884 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 15, 2021 Filed Apr 16, 2021 21:03 UTC | Pulmonx Corp LUNG · Entity 2359 | SaleCommon Stock | 1,000 | $43.70 | $43,700.00 |
DisclosureSEC source: 0001209191-21-026985 · doc4.xml · nonDerivative · entry 3 French Glendon E. III · CIK 0001805624 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 27,571 F4 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Glendon E. French III Children's Irrevocable Trust on December 15, 2020. F5 · ownership.nature: The shares are directly held by the Glendon E. French III Children's Irrevocable Trust dated 11-17-98 for which the Reporting Person is a trustee. Read SEC document |
| April 15, 2021 Filed Apr 16, 2021 21:03 UTC | Pulmonx Corp LUNG · Entity 2359 | SaleCommon Stock | 5,011 | $44.21 | $221,536.31 |
DisclosureSEC source: 0001209191-21-026985 · doc4.xml · nonDerivative · entry 2 French Glendon E. III · CIK 0001805624 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,224,884 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.13 to $44.38, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| April 15, 2021 Filed Apr 16, 2021 21:03 UTC | Pulmonx Corp LUNG · Entity 2359 | SaleCommon Stock | 19,989 | $43.64 | $872,319.96 |
DisclosureSEC source: 0001209191-21-026985 · doc4.xml · nonDerivative · entry 1 French Glendon E. III · CIK 0001805624 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,229,895 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.12 to $44.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| April 15, 2021 Filed Dec 3, 2021 23:46 UTC Amendment | Pulmonx Corp LUNG · Entity 2359 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $2.20 | $0.00 |
DisclosureSEC source: 0001209191-21-067978 · doc4a.xml · derivative · entry 4 French Glendon E. III · CIK 0001805624 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 184,999 Underlying: Common Stock · 25,000 shares Expires 2030-08-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares subject to the option are immediately exercisable and vest in 48 equal monthly installments beginning on August 28, 2020, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| April 15, 2021 Filed Dec 3, 2021 23:46 UTC Amendment | Pulmonx Corp LUNG · Entity 2359 | SaleCommon Stock | 5,011 | $44.21 | $221,536.31 |
DisclosureSEC source: 0001209191-21-067978 · doc4a.xml · nonDerivative · entry 3 French Glendon E. III · CIK 0001805624 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,249,884 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.13 to $44.38, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| April 15, 2021 Filed Dec 3, 2021 23:46 UTC Amendment | Pulmonx Corp LUNG · Entity 2359 | SaleCommon Stock | 19,989 | $43.64 | $872,319.96 |
DisclosureSEC source: 0001209191-21-067978 · doc4a.xml · nonDerivative · entry 2 French Glendon E. III · CIK 0001805624 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,254,895 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.12 to $44.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| April 15, 2021 Filed Dec 3, 2021 23:46 UTC Amendment | Pulmonx Corp LUNG · Entity 2359 | Exercise / conversionCommon Stock | 25,000 | $2.20 | $55,000.00 |
DisclosureSEC source: 0001209191-21-067978 · doc4a.xml · nonDerivative · entry 1 French Glendon E. III · CIK 0001805624 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,274,884 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.